ClinicalTrials.gg

Program

zelenectide pevedotin

Also written as “Zelenectide pevedotin”, “BT8009” and “Zelenectide pevedotin (BT8009)”.

Its studies are mostly in Urinary Bladder Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms, led by BicycleTx.

Furthest: phase 2, since Sep 14, 20205 company-led studies, 5 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BicycleTx55 open or runningphase 2since Sep 14, 2020Sep 14, 2020Jan 2027phase 2 · NCT04561362

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2020First study: phase 2 study in Urinary Bladder NeoplasmsFirst studyNCT04561362 · 329 enrolled · United States, Canada, France and more
  2. Jan 12, 2024Phase 2 study in Urinary Bladder NeoplasmsNCT06225596 · 375 enrolled · United States, Argentina, Australia and more
  3. Feb 18, 2025Phase 2 study in Breast NeoplasmsNCT06840483 · 66 enrolled · United States, Australia, Belgium and more
  4. Apr 16, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06933329 · 73 enrolled · France, Spain
  5. Jun 26, 2026Phase 2 study in Advanced Solid TumorsNCT07681674 · 16 planned

Ahead

  1. Jan 2027Primary completion: phase 2 study in Urinary Bladder NeoplasmsNCT04561362
  2. Mar 2028Primary completion: phase 2 study in Urinary Bladder NeoplasmsNCT06225596
  3. Jun 30, 2028Primary completion: phase 2 study in Breast NeoplasmsNCT06840483
  4. Aug 31, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06933329

TargetBeta

BTC →NECTIN4 →read by rule
“A Bicycle toxin conjugate (BTC) composed of a zelenectide, a synthetic, bicyclic peptide targeting the cell adhesion molecule nectin-4 (PVRL4) and ”NCIt, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07681674Advanced Solid Tumors2Not yet recruitingMay 30, 203016
NCT06933329Carcinoma, Non-Small-Cell Lung · France, Spain2Active, not recruitingAug 31, 202873
NCT06840483Breast Neoplasms · United States, Australia, Belgium and more2Active, not recruitingJun 30, 202866
NCT06225596Urinary Bladder Neoplasms · United States, Argentina, Australia and more2Active, not recruitingMar 2028375
NCT04561362Urinary Bladder Neoplasms · United States, Canada, France and more2Active, not recruitingJan 2027329

How it is read

Names in the registry

  • “Zelenectide pevedotin”, 4 entries
  • “BT8009”, 1 entry
  • “Zelenectide pevedotin (BT8009)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.